Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385712 | 1.00 | L3MBTL1 (0.36) | L3MBTL1CHRM1RAB9AMMEHTT | |
| SCHEMBL383047 | 0.98 | L3MBTL1 (0.39) | L3MBTL1CHRM1RAB9AMMEHTT | |
| SCHEMBL383046 | 0.98 | L3MBTL1 (0.39) | L3MBTL1CHRM1RAB9AMMEHTT | |
| Alanine SCHEMBL4954723 | 0.92 | LTA4H (0.35) | L3MBTL1CHRM1RAB9AMMEHTT | |
| Glycine SCHEMBL4955873 | 0.89 | GLRA1 (0.36) | L3MBTL1CHRM1MMELTA4HDPP7 | |
| Threonine SCHEMBL4955781 | 0.86 | SLC7A5 (0.36) | LTA4HDPP7 | |
| Serine SCHEMBL4956028 | 0.84 | DPP7 (0.40) | L3MBTL1CHRM1MMELTA4HDPP7 | |
| Pyrrole SCHEMBL28327955 | 0.84 | L3MBTL1 (0.38) | L3MBTL1HTTNPC1ALDH1A1GAA | |
| SCHEMBL15794748 | 0.81 | CHRM5 (0.41) | RAB9APOLB | |
| SCHEMBL15794935 | 0.81 | CHRM5 (0.41) | RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| WO-2010132580-A2 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-11-18 | — | — | WO | claimed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | claimed |
| US-7439226-B2 | Serine protease inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-10-21 | — | — | US | claimed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2007055578-A1 | CYCLIC ANTIMICROBIAL PEPTIDES DERIVED FROM LACTOFERRIN | LEIDS UNIVERSITAIR MEDISCH CENTRUM (NL) | 2007-05-18 | — | — | WO | claimed |
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | claimed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| WO-2006043933-A1 | SERINE PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-27 | — | — | WO | claimed |
| US-20050130883-A1 | Serine protease inhibitors | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2005-06-16 | — | — | US | claimed |
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | UNIV MICHIGAN (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4680108-A1 | PEPTIDE MULTIMER PRODUCTS AND METHODS | The Regents of The University of Michigan (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | disclosed |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2025-08-21 | — | — | US | disclosed |
| WO-2006083317-A9 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006043933-A1 | SERINE PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050130883-A1 | Serine protease inhibitors | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | TP53, TP53BP1, DDIT3 | L3MBTL1 355/4885CHRM1 3749/4885RAB9A 2700/4885 |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | ERBB2, EGFR, ERBB3 | L3MBTL1 3066/4885CHRM1 4702/4885RAB9A 2164/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | L3MBTL1 75/4885CHRM1 2969/4885RAB9A 2318/4885 |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | L3MBTL1 1472/4885CHRM1 4449/4885RAB9A 757/4885 |
| US-20050130883-A1 | Serine protease inhibitors | PRSS1, TASP1, METAP1 | L3MBTL1 1590/4885CHRM1 4600/4885RAB9A 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.